Cargando…

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer (CRPC) patients’ survival an extra 4.8 months, it might also result in some adverse effects via inducing the neuroendocrine differentiation (NED). Here we found that lncRNA-p21 is highly expressed in the NEPC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Jie, Wang, Keliang, Yeh, Shuyuan, Sun, Yin, Liang, Liang, Xiao, Yao, Xu, Wanhai, Niu, Yuanjie, Cheng, Liang, Maity, Sankar N., Jiang, Runze, Chang, Chawnshang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561926/ https://www.ncbi.nlm.nih.gov/pubmed/31189930 http://dx.doi.org/10.1038/s41467-019-09784-9

Ejemplares similares

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR
por: You, Bosen, et al.
Publicado: (2021)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers
por: Soundararajan, Rama, et al.
Publicado: (2018)

TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures
por: Sha, Kai, et al.
Publicado: (2015)

Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression
por: Wu, Gang, et al.
Publicado: (2019)

Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population
por: Li, Lei, et al.
Publicado: (2015)

Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals
por: Deng, Gang, et al.
Publicado: (2021)

Correction: Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population
por: Li, Lei, et al.
Publicado: (2016)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
por: Ito, Yusuke, et al.
Publicado: (2018)

Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression
por: Zhang, Meng, et al.
Publicado: (2021)

The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
por: Leach, D. A., et al.
Publicado: (2021)

The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer
por: Liu, Bianjiang, et al.
Publicado: (2020)

BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts
por: WEN, SIMENG, et al.
Publicado: (2015)

Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer
por: Ye, Chen, et al.
Publicado: (2022)

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
por: Lin, Changyi, et al.
Publicado: (2020)

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models
por: Xu, Pengfei, et al.
Publicado: (2023)

Role of lncRNA and EZH2 Interaction/Regulatory Network in Lung Cancer
por: Su, Min, et al.
Publicado: (2018)

LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease
por: Zou, Dongmei, et al.
Publicado: (2022)

STAT3-Induced Upregulation of lncRNA CASC9 Promotes the Progression of Bladder Cancer by Interacting with EZH2 and Affecting the Expression of PTEN
por: Yuan, Bo, et al.
Publicado: (2020)

LncRNA Snhg6 regulates the differentiation of MDSCs by regulating the ubiquitination of EZH2
por: Lu, Wei, et al.
Publicado: (2021)

LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2
por: Wang, Xin, et al.
Publicado: (2016)

LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27
por: Zhang, Fei, et al.
Publicado: (2017)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L, et al.
Publicado: (2013)

Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemo-resistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals
por: Cui, Yun, et al.
Publicado: (2016)

LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer
por: Wang, Dejie, et al.
Publicado: (2015)

LncRNA NEAT1 Promotes Endometrial Cancer Cell Proliferation, Migration and Invasion by Regulating the MiR-144-3p/EZH2 Axis
por: Wang, Wei, et al.
Publicado: (2019)

TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
por: Lee, Geun Taek, et al.
Publicado: (2019)

Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2
por: Wu, Yuanyuan, et al.
Publicado: (2017)

HERES, a lncRNA that regulates canonical and noncanonical Wnt signaling pathways via interaction with EZH2
por: You, Bo-Hyun, et al.
Publicado: (2019)

The association between lncRNA H19 and EZH2 expression in patients with EBV-positive laryngeal carcinoma
por: Hotoboc, Irina E., et al.
Publicado: (2021)

LncRNA: An All-rounder in Rheumatoid Arthritis
por: Liang, Junyu, et al.
Publicado: (2019)

Editorial: The Role of lncRNA in Cancer Metabolism
por: Huang, Guo-Liang, et al.
Publicado: (2021)

Increased CK5/CK8-Positive Intermediate Cells with Stromal Smooth Muscle Cell Atrophy in the Mice Lacking Prostate Epithelial Androgen Receptor
por: Niu, Yuanjie, et al.
Publicado: (2011)

LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex
por: Shang, Zhiqun, et al.
Publicado: (2019)

The roles of lncRNA in hepatic fibrosis
por: Peng, Hu, et al.
Publicado: (2018)

LncRNA GAS5 facilitates nasopharyngeal carcinoma progression through epigenetically silencing PTEN via EZH2
por: Zhao, Dan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tum5vmcc949d8g7ubk6lt5mp4t